Skip to main content
Fig. 1 | Journal of Nanobiotechnology

Fig. 1

From: A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies

Fig. 1

Growth inhibition of pancreatic cancer cell lines by EF24 and by curcumin. A panel of ten pancreatic cancer cell lines was exposed to increasing doses of a curcumin or b EF24 for 72 h, and cell viability was determined using MTS assays. Across all cell lines, EF24 inhibited viability at approximately 10- to 20-fold lower IC50 as compared to curcumin. c Similar effects were observed in clonogenic assays, where EF24 abrogated the ability of pancreatic cancer cells to form colonies at concentrations that were about tenfold lower than the required curcumin doses (all experiments were done in triplicates and repeated at least once; the figure shows pictures from two representative experiments)

Back to article page